#ZENONIA 4 DEN OF TRIALS TRIAL#
To compare the rates of vaginal recurrence in women with high-intermediate risk endometrial cancer, treated after surgery with molecular-integrated risk profile-based recommendations for either observation, vaginal brachytherapy or external pelvic beam radiotherapy or with standard adjuvant vaginal brachytherapy STUDY HYPOTHESIS: Adjuvant treatment based on a molecular-integrated risk profile provides similar local control and recurrence-free survival as current standard adjuvant brachytherapy in patients with high-intermediate risk endometrial cancer, while sparing many patients the morbidity of adjuvant treatment and reducing healthcare costs.Ī multicenter, international phase III randomized trial (2:1) of molecular-integrated risk profile-based adjuvant treatment (experimental arm) or adjuvant vaginal brachytherapy (standard arm). However, there is still considerable overtreatment and also some undertreatment, which may be reduced by tailoring adjuvant treatment to the patients' risk of recurrence based on molecular tumor characteristics. Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial cancer to maximize local control and has only mild side effects and no or limited impact on quality of life.
26 Obstetrics & Gynecology, University Medical Centre Groningen, University of Groningen, Groningen, Groningen, The Netherlands.25 Biomedical Data Sciences, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
24 Medical Statistics, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.23 Comprehensive Cancer Centre Utrecht, Utrecht, The Netherlands.22 Radiation Oncology, Institut Gustave-Roussy, Villejuif, Île-de-France, France.20 Radiation Oncology, University Hospital Ghent, Gent, Oost-Vlaanderen, Belgium.19 Radiation Oncology, Zuidwest Radiotherapeutic Institute, Vlissingen, Zeeland, The Netherlands.18 Radiation Oncology, Isala Klinieken, Zwolle, Overijssel, The Netherlands.17 Women's Health, Rotkreuzklinikum Munchen, Munchen, Bayern, Germany.16 Radiation Oncology, Radboudumc, Nijmegen, Gelderland, The Netherlands.15 Radiation Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands.14 Radiation Oncology, Haaglanden Medical Center, Den Haag, Zuid-Holland, The Netherlands.13 Gynecologic Oncology Centre, Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.12 Radiation Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Groningen, The Netherlands.11 Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands.10 Women's Health, Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany.
9 Radiation Oncology, Institute Verbeeten, Tilburg, Noord-Brabant, The Netherlands.8 Radiation Oncology, Radiotherapy Institute Friesland, Leeuwarden, Friesland, The Netherlands.7 Radiation Oncology, Catharina Hospital, Eindhoven, Noord-Brabant, The Netherlands.6 Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Noord-Holland, The Netherlands.5 Radation Oncology, Radiotherapy Group, Arnhem, Gelderland, The Netherlands.4 Radiation Oncology, Maastricht University Medical Centre+, Maastricht, Limburg, The Netherlands.3 Radiation Oncology, Erasmus Medical Center - Cancer Institute, Rotterdam, Zuid-Holland, The Netherlands.1 Radiation Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands 2 Radiation Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
0 kommentar(er)
